相关实验视频
Updated: Jun 28, 2025

05:37
An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
2.1K
用贝叶斯概率定理来预测库辛病的缓解和复发的客观方法
N Gupta1, B D Konsam1, R Walia2
1Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), 1010, Nehru Extension Block, Chandigarh, 160012, India.
Journal of endocrinological investigation
|April 15, 2024
概括
贝叶斯定理可以预测经过跨形手术后的库辛病缓解,灵敏度为82%和特异性为94%. 这种方法提供了一个客观的方法来预测患者的缓解和复发概率.
科学领域:
- 内分泌学 在内分泌学.
- 神经外科 神经外科
- 生物统计学 生物统计学
背景情况:
- 库辛病是一种罕见的内分泌疾病,由过度皮质醇产生引起.
- 脑膜外科手术 (TSS) 是主要的治疗方法,但预测长期缓解和复发仍然具有挑战性.
- 准确预测缓解和复发对于患者的管理和结果至关重要.
研究的目的:
- 开发和验证一个预测模型,用于TSS后库希病缓解和复发概率.
- 应用贝叶斯定理和条件概率方程,结合多个临床,生化,放射学和病理学参数.
- 为评估库辛病患者手术后结果提供一个客观的方法.
主要方法:
- 一个单一中心的宏观研究,涉及145名为库辛病接受TSS治疗的患者.
- 识别和二进制编码十个预测参数 (临床,生化,放射学,组织病理学).
- 应用贝叶斯定理来计算个体患者缓解和复发的概率.
主要成果:
- 预测模型实现了0.68的切断概率,预测缓解的灵敏度为82%,特异性为94%.
- 在1年内缓解的81名患者中,23人经历了疾病复发.
- 贝叶斯方程在预测这些23例复发方面取得了有限的成功,只准确识别了3例病例.
结论:
- 贝叶斯定理有效地预测了高灵敏度和特异性的TSS后的库辛病缓解.
- 该研究提供了一个客观的工具来预测缓解和复发,将权重分配给各种参数.
- 可能需要进一步细化,以提高使用这种概率模型的复发预测的准确性.
相关概念视频
Probability Laws
40.8K
Overview
40.8K
Kaplan-Meier Approach
135
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
135
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Actuarial Approach
77
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
77
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
Comparing the Survival Analysis of Two or More Groups
179
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
179

